Please login to the form below

Not currently logged in
Email:
Password:

early access

This page shows the latest early access news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Airbus relocation woes, inflated taxes will pay for NHS boost, NICE OK's Sanofi's Dupixent and more

Daily Brief: Airbus relocation woes, inflated taxes will pay for NHS boost, NICE OK's Sanofi's Dupixent and more

The drug gained a Promising Innovative Medicine designation from the UK’s regulator the MHRA, an early access scheme which operated before it gained EU marketing approval.

Latest news

More from news
Approximately 73 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    increased. patient access. “They need to recognise that this is the opportunity of the century and they should seize it.”. ... We are looking at a hybrid solution that offers favourable pricing and increased access for the patients.

  • Accelerating diagnosis in rare disease Accelerating diagnosis in rare disease

    Diagnosis of rare disease is challenging; physicians may only see a handful of cases in their career and information surrounding them is often lacking or difficult to access. ... CROs and trial design • Early access and regulation • Value

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Ambitious strategy. “Companies need to set an ambitious strategy for pricing and market access early on, ”Barham continues. ... No system is perfect, ”Barham concludes. “But there is scope for improvements in all countries to try to reach a

  • Can UK pharma rise to the post-Brexit challenge? Can UK pharma rise to the post-Brexit challenge?

    Marketing authorisations. With no access to the single market, UK pharmaceutical companies will be forced to make two separate regulatory submissions - one to the EU and one to the UK. ... 4.The Early Access to Medicine Scheme (EAMS) could be adopted

  • Lighting the way Lighting the way

    current Patient Access Schemes that pharma companies agree with the Department of Health with input from NICE. ... Ultimately the government says the Review's recommendatiosn have the potential to cut four years from the process, through a funded Early

More from intelligence
Approximately 5 fully matching, plus 35 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • TVF Communications shortlisted for the second year in a row for Writing Excellence award at Communique 2017

    A primary aim was to overcome the challenges associated with lack of early diagnosis, patient access, availability of treatment and patient stigma, which in partnership with AbbVie was made possible.

  • How can pharma help the NHS drive much-needed change in mental health services?

    The PoE programme aims to achieve this through prevention, early intervention, access to crisis care on a 24/7 basis and better integration of mental and physical healthcare. ... Changes that could help to achieve PoE. Early intervention is key and GPs

  • OPEN Access Consulting

    OPEN Access Consulting. OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. ... What OPEN Access Consulting do:. We have unrivalled experience in the delivery of market access programmes from early phase insights to

  • Accession

    The early industry pioneers of market access, are the creative force behind Accession. ... Today we are a specialist team of market access innovators, go-getters, strategists, scientists, analysts, and economists.

  • Determining value to withstand all tests

    The article in Pharmaceutical Marketing Europe discusses the need for functions to better join forces early in the access continuum in the interest of defining and delivering value that is going

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics